Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Peer Review reports

Original Submission
19 Dec 2016	Submitted	Original manuscript
27 Jan 2017	Author responded	Author comments - Christian Kelly-Morland
Resubmission - Version 2
27 Jan 2017	Submitted	Manuscript version 2
Publishing
17 May 2017	Editorially accepted
2 Jun 2017	Article published	10.1186/s12885-017-3371-9

Back to article page